As of November 2020, there are no generic versions of Vascepa (icosapent ethyl) available in the United States [2][3]. Vascepa is a prescription medication used to lower high triglyceride levels in adults [1]. It was approved by the U.S. Food and Drug Administration (FDA) in 2012 [1]. The drug's patent is set to expire in 2030 [2]. Despite the expiration date, the manufacturer, Amarin, has been fighting to protect its exclusivity on the drug [2]. In March 2020, a U.S. District Court ruled in favor of Amarin, stating that the company's patents on Vascepa were valid and enforceable [2]. However, in September 2020, a U.S. appeals court overturned the previous ruling, stating that Amarin's patents were invalid [2]. Amarin has since filed a petition with the U.S. Supreme Court to review the case [2]. Until a generic version is approved or the legal battle over exclusivity is resolved, Vascepa will remain available only as a brand-name medication [2][3].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://professionals.optumrx.com/content/dam/optum3/professional-optumrx/news/rxnews/new-generics/newgenerics_vascepa_2020-1106.pdf
[3] https://www.drugs.com/availability/generic-vascepa.html